Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model

Indoleamine 2,3-dioxygenase (IDO) is involved in tumor immune escape and resistance to chemotherapy, and is clinically correlated with tumor progression. IDO inhibitors show marginal efficacy as single agents; therefore, combinations of these inhibitors with other therapies hold promise for cancer t...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Xiangjing, Du, Guangying, Ye, Liang, Sun, Shanyue, Liu, Qiaofeng, Wang, Hongbo, Wang, Wenyan, Wu, Zimei, Tian, Jingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815254/
https://www.ncbi.nlm.nih.gov/pubmed/28604143
http://dx.doi.org/10.1177/0394632017714696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815254/
https://www.ncbi.nlm.nih.gov/pubmed/28604143
http://dx.doi.org/10.1177/0394632017714696

Ejemplares similares